It’s no legend: Abbott has captured Bigfoot Biomedical by striking a deal to acquire the diabetes management tech maker.

这不是传说：雅培通过收购糖尿病管理技术制造商，捕获了Bigfoot Biomedical。

Abbott and Bigfoot announced the purchase Tuesday, though they didn’t disclose its financial terms. The sale is expected to be completed sometime in the third quarter of this year.

雅培和比格福特宣布了这一购买，尽管他们没有透露其财务条款。预计该销售将在今年第三季度的某个时候完成。

“The acquisition of Bigfoot Biomedical will combine two leaders in different aspects of diabetes care: continuous glucose monitoring and insulin dosing support,” Jared Watkin, senior vice president of Abbott’s diabetes care business, said in the announcement. “Bringing our companies together will allow us to further develop connected solutions for making diabetes management even more personal and precise.”.

雅培糖尿病护理业务高级副总裁Jared Watkin在公告中说：“收购Bigfoot Biomedical将结合糖尿病护理不同方面的两位领导者：持续血糖监测和胰岛素剂量支持。“将我们的公司聚集在一起将使我们能够进一步开发相关的解决方案，使糖尿病管理更加个人化和精确。”。

Bigfoot’s flagship Unity system—which was initially cleared by the FDA for use with an iPhone app in 2021 before being expanded to Android operating systems this year—centers around “smart” caps that snap onto most disposable long- and rapid-acting insulin pens.

Bigfoot的旗舰Unity系统最初于2021年被FDA批准与iPhone应用程序一起使用，然后今年扩展到Android操作系统，其中心是围绕“智能”帽子，这些帽子可以卡到大多数一次性长效和速效胰岛素笔上。

Once installed, the pen caps can be tapped against a continuous glucose monitor sensor on the back of a user’s arm for a real-time blood sugar reading. The readings show up both on the pen cap’s digital display—which also keeps track of how long it’s been since the user’s last insulin dose—and in the connected smartphone app, giving users the information they need to make decisions about their next insulin doses..

安装后，可以将笔盖轻拍用户手臂背面的连续葡萄糖监测仪传感器，以实时读取血糖。读数显示在笔帽的数字显示屏上，该数字显示屏还可以跟踪用户自上次胰岛素剂量以来的持续时间以及连接的智能手机应用程序中的时间，为用户提供有关下一次胰岛素剂量决策所需的信息。。

The Unity app compiles those data into longer-term charts, highlighting trends in a user’s glucose levels and insulin dosage times, and it also sends out alerts if their real-time blood sugar levels leave a predetermined healthy range.

Unity app将这些数据编译成长期图表，突出显示用户血糖水平和胰岛素剂量时间的趋势，如果实时血糖水平离开预定的健康范围，它还会发送警报。

Bigfoot’s system has long been designed for use solely with CGMs from Abbott’s FreeStyle Libre line. They struck a partnership deal in 2017, after which Abbott continued to show support for the startup by chipping into its $55 million series B round in 2018 and leading a series C of the same amount two years later..

Bigfoot的系统长期以来一直设计用于Abbott FreeStyle Libre系列的CGM。他们于2017年达成合作协议，之后雅培继续通过在2018年削减5500万美元的B轮系列并在两年后领导相同金额的C系列来支持初创企业。。

“Bigfoot Biomedical is the first company to design, develop and deliver a novel insulin delivery solution built around continuous glucose monitoring,” Jeffrey Brewer, the company’s CEO, said in Tuesday’s release. “We selected Abbott as our CGM partner because both companies share a vision to provide simple, affordable and easy-to-use tools for people with diabetes.

该公司首席执行官杰弗里·布鲁尔（Jeffrey Brewer）在本周发布时说：“Bigfoot Biomedical是第一家设计，开发和提供围绕连续血糖监测的新型胰岛素输送解决方案的公司。“我们选择雅培作为我们的CGM合作伙伴，因为两家公司都有共同的愿景，为糖尿病患者提供简单，负担得起且易于使用的工具。

We look forward to continuing to innovate together and to the scale Abbott can provide, bringing Bigfoot Unity to as many people who may benefit.”.

我们期待着不断创新，并达到雅培可以提供的规模，为尽可能多的人带来巨大的团结。

Ahead of the Abbott acquisition, Bigfoot had recently added to its own diabetes tech portfolio. In March, the startup said it had acquired an algorithm from developers at McGill University for an undisclosed amount.

在雅培收购之前，Bigfoot最近已添加到自己的糖尿病技术产品组合中。3月，该初创公司表示，它已从麦吉尔大学的开发人员处获得未公开金额的算法。

The algorithm tracks how people with diabetes respond to certain insulin doses to generate future dosing suggestions. Brewer suggested at the time that the algorithm could be added to the Bigfoot Unity system, further simplifying the insulin dose calculation process and diabetes management overall.

该算法跟踪糖尿病患者对某些胰岛素剂量的反应，以产生未来的剂量建议。Brewer当时建议该算法可以添加到Bigfoot统一系统中，进一步简化胰岛素剂量计算过程和整体糖尿病管理。